For the first time these results show a significant additive effect in the treatment of advanced NSCLC patients by combining the two different treatment concepts of anti-angiogenesis and inhibition of tumor cell proliferation based on EGFR driver mutations. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.